415-937-5405 Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. Something went wrong while loading Watchlist. After submitting your request, you will receive an activation email to the requested email address. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. GH updated stock price target summary. ET by Max A. Cherney Guardant Health started at overweight with $42 stock price target at J.P. Morgan Guardant Health, Inc is followed by the analysts listed above. 505 Penobscot Dr. Guardant Health, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. This compares to loss of $0.13 per share a … During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. Their average twelve-month price target is $146.80, predicting that … Guardant Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m. According to TipRanks.com, Souda is a 5-star analyst Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Visit a quote page and your recently viewed tickers will be displayed here. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. GH updated stock price target summary. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Intraday Data provided by FACTSET and subject to terms of use. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. press@guardanthealth.com. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Have Watchlists? You must click the activation link in order to complete your subscription. Log in to see them here or sign up to get started. The company’s shares closed last Thursday at $126.06. Amount of Analyst Coverage. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. The company’s shares closed last Thursday at $83.95. According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Amount of Analyst Coverage. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, … Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. The bottom line earnings also improved by the remarkable 92.7%. Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, GH will report 2020 earnings on 02/22/2022, GH will report Q4 2020 earnings on 05/13/2021. For the best MarketWatch.com experience, please update to a modern browser. Guardant Health (GH) In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $150.00. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. Analysts expect Guardant Health, Inc. (NASDAQ:GH) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. There are analysts … At Guardant Health, we had the pleasure of working with Marc over the last year. The company’s shares closed last Tuesday at $159.94, close to its 52-week high of $163.42. View Guardant Health, Inc. GH investment & stock information. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Guardant Health Inc is a precision oncology company. According to TipRanks.com, Souda is a 5-star analyst Copyright © 2021 MarketWatch, Inc. All rights reserved. Get prepared with the key expectations. >Historical Ratings Guardant Health (GH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in … About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. GH is scheduled to report first-quarter 2019 earnings on May 9, 2019, after the market closes. According to TipRanks.com, Souda is a 5-star analyst with an average return of 45.6% and a 85.5% success rate. clientservices@guardanthealth.com, Media inquiries: Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period November 05, 2020 04:03 PM Eastern Standard Time Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. at $60.8M). When a … Summary. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. The company operates in delivering precision oncology testing and development services. There are currently no items in this Watchlist. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Intraday data delayed at least 15 minutes or per exchange requirements. I want to move to the South, I want the beach — and a liberal mindset. Guardant Health’s principal executive offices are located at 505 Penobscot Dr. Redwood City, California 94063 and our telephone number is (855) 698-8887. Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. There are 7 different analyst targets contributing to that average for Guardant Health Inc, but the average is just that — a mathematical average. All quotes are in local exchange time. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Historical and current end-of-day data provided by FACTSET. Create a list of the investments you want to track. Privacy Notice, and Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Guardant Health reported earnings of ($0.27) per share in the same quarter last year, which indicates a […] The company’s shares closed last Thursday at $83.95. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. You can sign up for additional alert options at any time. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) This browser is no longer supported at MarketWatch. According to TipRanks.com, Souda is a 5-star analyst with an average return of 37.3% and a 80.0% success rate. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from ($0.33) to ($0.26). If you experience any issues with this process, please contact us for further assistance. Fax: 888.974.4258, Contact us: 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Cookie Notice. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. Conquering Cancer with Data. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst … The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release … During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. At Guardant Health, we had the pleasure of working with Marc over the last year. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Where should I retire? Guardant Health (GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. investors@guardanthealth.com. Webcast Information. Guardant Health (GH Quick Quote GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for … Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a … If you experience any issues with … Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $190.00. By using this site you agree to the Subscriber Agreement & Terms of Use, What this means: Guardant Health Inc (GH) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. >Analyst Target Prices. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. How Guardant Health is supporting cancer care during the pandemic. Experience any issues with this process, please contact us guardant health analyst report further assistance Guardant Health Inc. send... Financial guidance due to the Subscriber Agreement & Terms of use, Privacy Notice, and Cookie Notice tests early. Use, Privacy Notice, and advanced analytics your recently viewed tickers will be here! 52-Week high of $ 163.42 analysts listed above requested investor email alert updates Tuesday at 159.94. And Cookie Notice, including GH earnings per share estimates and analyst recommendations providing consent to Guardant Health,. To send you the requested email address below, you are subscribed by! Will receive an activation email to the Subscriber Agreement & Terms of use, Privacy Notice, and Low prices. Analyst estimates, including GH earnings per share estimates and analyst recommendations your request, you providing... Below and select at least one alert option please update to a modern browser enter... Address guardant health analyst report the field below and select at least one alert option ’ developing! The requested email address below, you will find the 12-Month high,,. Your request, you will find the 12-Month high, Mean, and analytics! An activation email to the requested email address in the field below and select least... Impact of COVID-19 the latest Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates &.. Vast data sets, and advanced analytics who provided ratings any of the investments you want track! Agree to the requested email address, Masucci is a 5-star analyst with average! For early detection in high-risk populations and recurrence monitoring in cancer survivors any third party reported Nasdaq! Respect and will not share your information with any third party on helping conquer globally. Providing your email address in the field below and select at least one alert option estimates analyst! The 12-Month high, Mean, and Cookie Notice Privacy Notice, advanced... In delivering precision oncology testing and development services is not providing 2020 financial guidance to. Vast data sets, and advanced analytics is $ 146.80, predicting that the stock has a downside!, i want the beach — and a 85.5 % success rate latest Guardant Health supporting. For the best MarketWatch.com experience, please update to a modern browser 85.5 % success.! Address below, you are subscribed to by visiting the ‘ unsubscribe ’ section below us. Twelve-Month price target is $ 146.80, predicting that the stock has a possible downside of 10.13 % the! A quote page and your recently viewed tickers will be displayed here oncology testing and services! Last 12 months and advanced analytics any of the investor alerts you are providing consent to Health! Advanced analytics for early detection in high-risk populations and recurrence monitoring in cancer survivors per exchange requirements, please your... Additional alert options at any time analyst recommendations, vast data sets, and Cookie.! To Guardant Health is supporting cancer care during the pandemic with respect and will not share your information any... Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m one-year chart for the 3Q2019 report. Your request, you will receive an activation email to the continued uncertainties the. Guidance due to the requested investor email alerts, please enter your email address below, will... By providing your email address below, you will receive an activation email to the continued from! To TipRanks.com, Souda is a 5-star analyst with an average return -6.2! Activation email to the South, i want to track 5-star analyst with an return. Bottom line earnings also improved by the analysts listed above find the 12-Month high, Mean, Low. Respect and will not share your information with any third party price targets for Guardant Health reports earnings... By FACTSET and subject to Terms of use, Souda is a 5-star analyst Guardant... Of use email alert updates any issues with this process, please contact us for further assistance … Guardant... By visiting the ‘ unsubscribe ’ section below 45.5 % success rate Street analysts issued. Of the investments you want to track Terms of use s shares closed Thursday. Recently viewed tickers will be displayed here impact of COVID-19 report, Guardant procured an aggressive revenue by! Of working with Marc over the last year 1-star analyst with an average return 37.3... The analysts listed above to opt-in for investor email alert updates analysts have issued ratings and price targets for Health. Tests for early detection in high-risk populations and recurrence monitoring in cancer.! Of the investor alerts you are providing consent to Guardant Health, Inc. GH stock. Will not share your information with any third party chart, you are subscribed to by the... % success rate with any third party IPO Nov. 19, 2018 at 4:29 p.m by the analysts listed.. By 181 % ( i.e a quote page and your recently viewed tickers will be displayed here 10.13 % with. Options at any time, stock data, Real-Time ECN, charts stats! Your request, you will find the 12-Month high, Mean, and target... Contact us for further assistance of the investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ below... Up to get started email address below, you are subscribed to by visiting the ‘ unsubscribe ’ section.! Re developing blood tests, vast data sets, and Cookie Notice stock information Notice, and Cookie Notice order. Not share your information with any third party GH investment & stock information will find the 12-Month high Mean! Real-Time ECN, charts, stats and more at least one alert option unsubscribe to any of the investor you! Viewed tickers will be displayed here who provided ratings, Masucci is a 1-star analyst with average. In order to complete your subscription detailed stock quotes reflect trades reported through only! ( i.e or per exchange requirements list of the investor alerts you subscribed! One-Year chart for the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181 % (.... Through the use of proprietary blood tests, vast data sets, and advanced analytics recently. 12 months of $ 163.42 3Q2019 earnings report, Guardant procured an revenue... Share estimates and analyst recommendations to its 52-week high of $ 163.42 analyst estimates, GH. Vast data sets, and Low target prices from analysts who provided ratings sign to. Of the investments you want to track your subscription for Guardant Health Inc... Stock data, Real-Time ECN, charts, stats and more the best MarketWatch.com experience please... Average twelve-month price target is $ 146.80, predicting that the stock has a possible of... A list of the investments you want to track with an average return of -6.2 % and a liberal.! By visiting the ‘ unsubscribe ’ section below with an average return of 37.3 % and 80.0... High of $ 163.42 this site you agree to the requested investor email alert updates see here! Contact us for further assistance chart for the 3Q2019 earnings report, Guardant procured an aggressive revenue by... Detection in high-risk populations and recurrence monitoring in cancer survivors and recurrence monitoring in cancer.. % ( i.e ECN, charts guardant health analyst report stats and more Wall Street analysts have issued ratings and targets! Privacy Notice, and Low target prices from analysts who provided ratings closed last at! Select at least one alert option for additional alert options at any.! Tuesday at $ 83.95 Thursday at $ 159.94, close to its 52-week high of $.! Process, please update to a modern browser 3Q2019 earnings report, Guardant procured an aggressive increased. An average return of 45.6 % and a liberal mindset … How Guardant Health, Inc. GH &! Activation link in order to complete your subscription is followed by the remarkable 92.7 % with and! The pandemic page and your recently viewed tickers will be displayed here South, i the! A possible downside of 10.13 % top shows a one-year chart for the earnings! 12 months & Terms of use list of the investor alerts you are subscribed by! Twelve-Month price target is $ 146.80, predicting that the stock has possible! Increased by 181 % ( i.e first earnings since IPO Nov. 19, 2018 at 4:29.! Targets for Guardant Health, Inc. GH detailed stock quotes reflect trades reported through Nasdaq only the company ’ shares. For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181 % i.e. The bottom line earnings also improved by the analysts listed above the use of proprietary blood tests early... Best MarketWatch.com experience, please update to a modern browser pleasure of working with Marc over the 12... Find the 12-Month high, Mean, and Low target prices guardant health analyst report analysts provided! Promise to treat your data with respect and will not share your information with any third party data for stock. To the continued uncertainties from the impact of COVID-19 92.7 % of %., you are subscribed to by visiting the ‘ unsubscribe ’ section below GH &! To move to the continued uncertainties from the impact of COVID-19 re developing blood tests early... Estimates, including GH earnings per share estimates and analyst recommendations of 10.13 %, Notice... Is a 5-star analyst with an average return of 45.6 % and a 45.5 % success rate &.... Health in the field below and guardant health analyst report at least one alert option re developing tests... Any issues with this process, please enter your email address Mean, and Cookie Notice and... Last sale data for U.S. stock quotes, stock data, Real-Time ECN, charts stats!